Using EMLA cream to reduce pain during lymphoscintigraphy for skin cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of EMLA topical cream in alleviating pain for patients undergoing Technetium 99 injections as part of a lymphoscintigraphy procedure for skin cancers. Participants are randomized into two groups: one receiving EMLA cream and the other receiving a placebo, both applied 30 minutes prior to the procedure. The study aims to determine if EMLA can significantly reduce the pain associated with the injections, which are necessary for identifying lymph nodes affected by cancer. This is the first investigation of EMLA cream's efficacy in this specific context, building on previous findings in breast cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Biologic males or females
* 18 - 99 years of age
* Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended.

Exclusion Criteria:

* Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic
* History of adhesive allergy
* Contraindication to Tc99 injection for sentinel lymph node mapping
* Incarcerated patients
* Patients incapable of independently providing consent
* Mucosal or genital lymphoscintigraphy site
* Pregnancy
* Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis
* Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure

Where it's running

• Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Carlo M Contreras, MD — Ohio State University Comprehensive Cancer Center
• Study coordinator: The Ohio State University Comprehensive Cancer Center
• Email: OSUCCCClinicaltrials@osumc.edu
• Phone: 800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early anti-PD1 therapy before surgery in high-risk stage II melanoma

  This study looks at real-world patients with high-risk stage II melanoma to see if starting anti-PD1 therapy before surgery changes outcomes compared with the usual timing.

  Recruiting AC Camargo Cancer Center · São Paulo, São Paulo · NCT07680699

• Guiding melanoma surgery in children using pathology and genetics

  This pediatric phase 2 trial tests whether using tumor pathology and genetic information to classify risk can guide safer, more appropriate surgery for localized skin melanocytic tumors.

  Recruiting at 13 sites Phase 2 Children's Oncology Group · Oakland, California and 12 other locations · NCT07621614

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.